Clinical trials: Cardiovascular Condition
Coronary Artery Disease
Hydroxyapatite Active Pro Healing Clinical Trial Program
The purpose of this first feasibility study is to evaluate the performance of Vesta™ \& VestaCOR™ (Hydroxy-Apetite coated GenX) stent in de novo native coronary artery lesions.
- Trial name
- HApFIM (NCT00474084)
- Testing
- Intravascular Coronary Stent
- Volunteers
- 70 people
- Sponsor
- BioSync Scientific Pvt. Ltd.
Coronary Artery Disease
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
This study will assess the differences between Fractional Flow Reserve (FFR) measurements made by the Navvus catheter and a commercially available pressure guidewire in up to 240 subjects where FFR is clinically indicated.
- Trial name
- ACIST-FFR (NCT02577484)
- Testing
- RXi System, Pressure Wire
- Where
- 12 sites in United States
- Volunteers
- 240 people
- Sponsor
- Acist Medical Systems
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Hypercholesterolemia
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease .
- Trial name
- NCT04358432
- Testing
- AK102, Statins and/or Ezetimibe
- Where
- 2 sites in China
- Volunteers
- 262 people
- Sponsor
- Akeso
Essential Hypertension
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
- Trial name
- OSCAR (NCT00139698)
- Testing
- olmesartan alone or in combination with hydrochlorothiazide
- Where
- 32 sites in Colombia, Ecuador and 8 more
- Volunteers
- 410 people
- Sponsor
- Pfizer
Coronary Artery Disease
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please in Korean Patients With Coronary In-stent Restenosis
The purpose of this study is to evaluate the safety and efficacy of Paclitaxel-coated balloon (Genoss® DCB) by demonstrating non-inferiority to in-segment late lumen loss at 6 months after the procedure in patients with in-stent…
- Trial name
- NCT04405063
- Testing
- Paclitaxel Coated PTCA Balloon Catheter
- Volunteers
- 82 people
- Sponsor
- Genoss Co., Ltd.
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
To identify the maximum tolerated dose (MTD) of oral azacitidine on different treatment schedules in Japanese subjects with hematological neoplasms
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT01908387
- Testing
- Oral azacitidine
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Celgene Corporation
Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)
The 3D Stent Study
The goal of this observational study is to assess the diagnostic performance of 3D Stent to detect stent under-expansion in patients undergoing percutaneous coronary intervention.
- Trial name
- NCT06898021
- Testing
- 3DStent
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 200 people
- Sponsor
- CoreAalst BV
Pulmonary Embolism
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in the treatment of pulmonary embolism (PE) and the prevention of the occurrence and the recurrence…
- Trial name
- NCT01516814
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Unfractionated heparin, Warfarin
- Where
- 31 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Bayer
Arthritis, Rheumatoid
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
To answer the question of overall benefit: risk of celecoxib when compared to two most commonly prescribe traditional (non-selective) nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of arthritis pain.
- Trial name
- PRECISION (NCT00346216)
- Testing
- celecoxib, Ibuprofen, Naproxen
- Where
- 1,066 sites in United States, Australia and 11 more
- Volunteers
- 24,081 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Multiple Myeloma
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to…
- Trial name
- Talisman (NCT06500884)
- Testing
- Talquetamab, Prophylaxis A, Prophylaxis B
- Where
- 38 sites in United States, Brazil and 5 more
- Volunteers
- 210 people
- Sponsor
- Janssen Research & Development, LLC
Tricuspid Regurgitation, Tricuspid Valve Disease
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
- Trial name
- VISTA-US (NCT05848284)
- Testing
- VDyne Transcatheter Tricuspid Valve Replacement System
- Where
- 11 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- VDyne, Inc.
Coronary Heart Disease
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
This double-blind, randomized, placebo-controlled, multi-center study will evaluate the safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome (ACS).
- Trial name
- NCT01323153
- Testing
- dalcetrapib
- Where
- 33 sites in United States, Czechia and 2 more
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Hypertension
A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension
The purpose of this study is to evaluate the effect of ION904 on plasma angiotensinogen (AGT) in participants with uncontrolled hypertension.
- Trial name
- NCT05314439
- Testing
- ION904
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypercholesterolemia
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00080275
- Testing
- Niacin Extended-Release and simvastatin Tablets
- Volunteers
- 600 people
- Sponsor
- Kos Pharmaceuticals
Coronary Disease
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
The primary focus of this study is to explore the safety of a range of doses of rNAPc2 in subjects who are managed in hospitals that most typically practice an early invasive strategy (catheterization during the index admission).
- Trial name
- NCT00116012
- Testing
- rNAPc2
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- ARCA Biopharma, Inc.
Hyponatremia
Study of Ascending Levels of Tolvaptan in Hyponatremia
The purpose of this study was to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal and to characterize and quantify the potential clinical benefits of this…
- Trial name
- SALT2 (NCT00201994)
- Testing
- Tolvaptan
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Aneurysm Cerebral
Study to Evaluate the TUBE Device Ability to Treat Unruptured, Wide-neck or Fusiform Aneurysms
To assess the safety and performance of the TUBE device in the endovascular treatment of unruptured, wide-neck or fusiform intracranial aneurysms located on the internal carotid artery (ICA) or its branches
- Trial name
- NV01 (NCT07079956)
- Testing
- TUBE Flow Diverter
- Where
- 3 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- NVMedTech
Well-controlled Hypertension
Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-controlled Hypertensive Patients
The purpose of this study is to evaluate the influence of aspirin on blood pressure in well-controlled hypertensive patients who receive low dose aspirin at different times of the day
- Trial name
- NCT00386529
- Testing
- Aspirin enteric coated pellests 100mg
- Where
- South Korea
- Volunteers
- 191 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Mitral Regurgitation, Mitral Valve Disease
Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System
The objective of this study is to evaluate the 5-year outcomes of participants with degenerative mitral valve disease treated with the NeoChord Artificial Chordae System, Model DS1000 in a post-market setting.
- Conditions
- Mitral Regurgitation, Mitral Valve Disease, Mitral Valve Insufficiency, Mitral Valve Prolapse
- Trial name
- AcChord (NCT04190602)
- Testing
- NeoChord Artificial Chordae Delivery System, Model DS1000
- Where
- 5 sites in Germany, Greece and 1 more
- Volunteers
- 500 people
- Sponsor
- NeoChord
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.